Calcium Dobesilate Versus Flavonoids for the Treatment of Early Hemorrhoidal Disease: A Randomized Controlled Trial

Shabbar H. Changazi 1, Samiullah Bhatti 2, Ayesha Choudary Sr. 2, Muhammad Naeem Afzal Rajput 2, Zahir Iqbal 3, Qamar A. Ahmed 4

1. Surgical Special Unit, Services Hospital, Lahore, PAK 2. Surgery, Services Hospital, Lahore, PAK 3. Internal Medicine, Services Hospital, Lahore, PAK 4. Surgery, Services Institute of Medical Services, Lahore, PAK

Corresponding author: Shabbar H. Changazi, shabbarchangazi246@gmail.com

Abstract

Background and Aim
Early hemorrhoidal disease is usually treated conservatively with fiber diet and medical therapy with flavonoids or calcium dobesilate. The purpose of this study was to compare the efficacy of these two agents in the treatment of early hemorrhoidal disease.

Materials and Methods
Patients having grade I and grade II hemorrhoidal disease were recruited in the study. One group received flavonoid therapy and the other group took calcium dobesilate treatment for three weeks. The symptoms and size of hemorrhoids were then assessed at the fourth week.

Results
In this study, 70.2% of patients were male and 29.8% of patients were female. Of the total patients, 58.65% of patients were below 45 years of age and 41.34% of patients were above 45 years of age. Moreover, 83.65% of patients had grade II hemorrhoids, whereas 16.34% of patients had grade I hemorrhoids; 80.8% of patients showed a decrease in frequency and amount of bleeding after being treated by flavonoids, whereas 67.3% showed a decrease in frequency and amount of bleeding after administration of calcium dobesilate. A decrease in the size of hemorrhoids was seen in 67.3% of patients after treatment with flavonoids and 38.46% after giving calcium dobesilate.

Conclusions
Treatment of early hemorrhoidal with flavonoid therapy was more effective in improving the symptoms of disease as compared to calcium dobesilate treatment.

Introduction
Hemorrhoids are a common disorder of the perianal region. They are symptomatic enlargement of the anal cushions [1]. Hemorrhoids can be classified into three types depending on the site of formation. Those arising above the dentate line are called internal hemorrhoids, those originating below the dentate line are called external hemorrhoids, and the mixed variety is believed to be present both above and below the dentate line.

Goligher’s classification is used to further classify the internal hemorrhoids into first-, second-, third-, and fourth-degree hemorrhoids depending on the degree of prolapse. Those that bleed but do not prolapse are known as first-degree hemorrhoids, those that prolapse but reduce spontaneously are known as second-degree hemorrhoids, those that require manual replacement are known as third-degree hemorrhoids, and those that are prolapsed and irreducible are known as fourth-degree hemorrhoids [2].

Studies on the prevalence of hemorrhoids are infrequent and have varying results. Johanson and Sonnenberg estimated a prevalence of 4.4% in U.S. adults [3]. Riss et al. in a study of 976 patients attending for colorectal cancer screening found that 58.93% suffered from hemorrhoids [4]. Hemorrhoids are asymptomatic in about 40% of individuals. Symptoms of hemorrhoids vary. The diagnosis of hemorrhoidal disease is based on patient history and clinical examination. Digital rectal examination and proctoscopy form the initial assessment.
The treatment of hemorrhoids varies depending on the degree and severity of symptoms. Lifestyle and dietary modification include increasing the intake of dietary fiber and oral fluids, reducing consumption of fat, having regular exercise, improving anal hygiene, abstaining from both straining and reading in the toilet, and avoiding medication that causes constipation or diarrhea [5,6].

Medications to reduce chronic venous insufficiency include venotonic agents such as flavonoids and calcium dobesilate. Numerous studies have shown the efficacy of flavonoids against early hemorrhoidal disease. In one of the meta-analysis, flavonoids demonstrated a remarkable response in early hemorrhoidal disease, with decreased risk of bleeding by 67%, persistent pain by 65%, and itching by 55% [7]. Calcium dobesilate in conjunction with fiber supplement was shown to be associated with a significant improvement in the inflammation of hemorrhoids [8].

The purpose of this randomized prospective study was to compare the efficacy of these two agents in the treatment of early hemorrhoidal disease.

**Materials And Methods**

This study was conducted in the Surgical Department of Services Institute of Medical Sciences Lahore, Pakistan, from December 2016 to November 2018. A total of 104 adult patients with first- and second-degree hemorrhoids diagnosed by clinical symptoms and anoscopy examination were included in this study. Ethical approval was taken from Institutional Review Board of the Services Institute of Medical Sciences. Patients of both genders and above 15 years of age with first- and second-degree hemorrhoids were recruited for the study. Patients with third- or fourth-degree hemorrhoids, patients having concurrent fistula or chronic anal fissure or inflammatory bowel disease, patients with previous anorectal surgery, patients having portal hypertension due to cirrhosis or portal vein thrombosis, and patients with a previous history of injection sclerotherapy or band ligation of hemorrhoids were excluded from the study. Written informed consent was taken from all patients. Rectosigmoidoscopy was included in the workup to rule out colorectal cause of symptoms. After initial proctoscopy examination, the patients were randomly allotted to one of the groups.

For group A (flavonoids; n = 52) flavonoids (Daflon) tablet 500 mg was given in the following dose: six tablets daily in the first week in BD dose and then four tablets daily in the second week, and, finally, two tablets daily in the third week. The symptoms and size of hemorrhoids were assessed in the fourth week. For group B (calcium dobesilate n=52) calcium dobesilate capsule (500 mg) was given in the dosage of two capsules twice a day for three weeks. The symptoms and size of hemorrhoids were assessed in the fourth week. The patients also received dietary and lifestyle advice. A high-fiber diet was advised to all patients in both groups and they were educated about the importance of fiber (fruits, vegetables, etc.) in healthy nutrition.

Frequency and percentages were calculated for quantitative data. A p-value of 0.05 or less was taken as significant. T-test and chi-square tests were applied in order to compare data of both groups. This work has been reported in line with the Consolidated Standards of Reporting Trials (CONSORT) guidelines and has registered in clinicaltrial.gov (NCT02782455).

**Results**

A total of 104 patients with early hemorrhoidal disease (grade I and grade II) were recruited in the study. Out of 104 patients, 73 (70.2%) were males and 31 (29.8%) were females. Out of the total 104 patients, 61 (58.65%) were below 40 years of age and 43 (41.34%) were above 40 years of age. Out of 104 patients, 87 (83.65%) had grade II hemorrhoids, whereas 17 (16.34%) had grade I hemorrhoids, as depicted in Table 1.
In the study, 45 (86.53%) patients showed a decrease in frequency of bleeding after being treated by flavonoids, whereas 35 (67.3%) showed a decrease in frequency of bleeding after administration of calcium dobesilate (chi-square test depicted a significance of 0.020). A similar pattern was observed in the patients treated with flavonoids and calcium dobesilate in terms of amount of bleeding. A decrease in the size of hemorrhoids was found in 35 (67.3%) patients after treatment with flavonoids and 20 (38.46%) after giving calcium dobesilate (p = 0.003), as shown in Table 2.

### TABLE 1: Treatment given according to gender, age group, and grade of hemorrhoidal disease of the patients

| Variables | Treatment | Total (n) | Percentage (%) | p-Value |
|-----------|-----------|-----------|----------------|---------|
| Gender    | Flavonoids | Calcium dobesilate |               |         |
| Male      | 38        | 35        | 73             | 70.2    |
| Female    | 14        | 17        | 31             | 29.8    |
| Total     | 52        | 52        | 104            | 100     |
| Age group | Flavonoids | Calcium dobesilate |               |         |
| Below 40 years | 31   | 30   | 61             | 58.7    |
| Above 40 years | 21  | 22  | 43             | 41.3    |
| Total     | 52        | 52        | 104            | 100     |
| Grade     | Flavonoids | Calcium dobesilate |               |         |
| Grade I   | 11        | 6         | 17             | 16.3    |
| Grade II  | 41        | 46        | 87             | 83.7    |
| Total     | 52        | 52        | 104            | 100     |

### TABLE 2: Response to treatment

| Variables | Treatment | Total (n) | Percentage (%) | p-Value |
|-----------|-----------|-----------|----------------|---------|
| Decrease in frequency of bleeding | Flavonoids | Calcium dobesilate |               |         |
| Yes       | 45        | 35        | 80             | 76.9    |
| No        | 7         | 17        | 24             | 23.1    |
| Total     | 52        | 52        | 104            | 100     |
| Decrease in amount of bleeding | Flavonoids | Calcium dobesilate |               |         |
| Yes       | 45        | 35        | 80             | 76.9    |
| No        | 7         | 17        | 24             | 23.1    |
| Total     | 52        | 52        | 104            | 100     |
| Decrease in size of hemorrhoids | Flavonoids | Calcium dobesilate |               |         |
| Yes       | 35        | 20        | 55             | 52.9    |
| No        | 17        | 32        | 49             | 47.1    |
| Total     | 52        | 52        | 104            | 100     |

### Discussion

This study showed that hemorrhoidal disease was more common in males (70.2%) as compared to females (29.8%). Similarly, a study conducted by Ravindranath and Rahul [9] also showed male predominance with a percentage of 66.7%. This pattern of male preponderance was also seen in other studies such as the study conducted by Ali et al. [10], who showed that there was 85% male prevalence, and Khan et al. [11], who also showed similar results with a male prevalence of 75.9%.

In this study, the most frequent age group affected is below 40 years of age (58.6%). These results are in concordance with studies conducted by Ravindranath and Rahul [9] and Ali et al. [10]. On the contrary, in the
study conducted by Khan et al. [11], hemorrhoidal disease was more common in the age group above 40 years (58.2%).

In our study, grade II hemorrhoidal disease (83.65%) was more common than grade I disease. This result is differing with the study carried out by Riss et al. [4], which showed that grade I disease (72.9%) is more common than other grades.

In the study, 86.55% of patients responded to flavonoid treatment in terms of decreased frequency and amount of bleeding, whereas 67.3% of patients responded to calcium dobesilate treatment. Furthermore, a decrease in the size of hemorrhoids was seen in 67.3% patients after treatment with flavonoids and 38.46% after giving calcium dobesilate therapy. These results were contradicting with results of the study conducted by Sarabia et al. [12], which showed that there was no significant difference in efficacy of flavonoids (73%) and calcium dobesilate (76%) in hemorrhoidal disease. They stated that both drugs were equally effective and well tolerated [12]. In a study conducted by Alonso-Coello et al. [7], flavonoids reduced the risk of bleeding and persisting symptoms by 67% and 58%, respectively. The study conducted by Patel et al. [15] showed that after six weeks of calcium dobesilate therapy, cessation of rectal bleeding plus lack of severe anitis occur in 48 patients, with a success rate of 81.35%. As per our study results, the efficacy of flavonoid therapy is superior to that of calcium dobesilate. However, more studies with larger samples are required to evaluate the efficacy of these drugs.

Conclusions
It can be concluded that flavonoid therapy was more effective in improving the symptoms of disease in terms of frequency of bleeding, amount of bleeding, and size of hemorrhoids as compared to calcium dobesilate treatment in patients with early hemorrhoidal disease.

Additional Information
Disclosures

Human subjects: Consent was obtained by all participants in this study. IRB, Services Institute of Medical Sciences Lahore, Pakistan issued approval IRB-96-2016. INSTITUTIONAL REVIEW BOARD SERVICES INSTITUTE OF MEDICAL SCIENCES SERVICES HOSPITAL, GHS-UL-AZAM (JAIL ROAD), LAHORE, PAKISTAN. Ph.: -92+042-99205402 Ref No. IRB-96/2016 Dated: 24.07.2016 To, Dr. Shabbar Hussain Changazi General Surgical Department, Services Hospital, Lahore. Subject: Ethical Approval for Research Protocol Titled "Calcium Dobesilate Vs Flavanoids for the treatment of Early Hemorrhoidal Disease: A Randomized Controlled Trial” Dear Dr. Shabbar, With reference to your request for approval of research proposal entitled "Ethical Approval for Research Protocol Titled "Calcium Dobesilate Vs Flavanoids for the treatment of Early Hemorrhoidal Disease: A Randomized Controlled Trial”. I would like to inform you that the IRB reviewed the documents submitted by you, including the protocol, informed consent forms and other documents. The IRB found he documents satisfactory and approved the conduct of this study. Yours sincerely, Prof. Syed Javed Raza Gardezi Co-chairman IRB, SIMS/Services Hospital, Lahore.

Animal subjects: All authors have confirmed that this study did not involve animal subjects or tissue.

Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

References
1. Lohsiriwat V: Hemorrhoids: from basic pathophysiology to clinical management . World J Gastroentero. 2012, 18:2009-17. 10.3748/wjg.v18.i17.2009
2. Madoff RD, Flesham JW, Clinical Practice Committee, American Gastroenterological Association: American Gastroenterological Association technical review on the diagnosis and treatment of hemorrhoids. Gastroenterology. 2004, 126:1463-73. 10.1053/j.gastro.2004.03.008
3. Johanson JF, Sonnenberg A: The prevalence of haemorrhoids and chronic constipation: an epidemiologic study. Gastroenterology. 1990, 98:380-6. 10.1016/S0016-5085(18)3807-6
4. Riss S, Weiser FA, Schwabe M, Riss T, Mittlböck M, Steiner G, Stift A: The prevalence of hemorrhoids in adults. Int J Colorectal Dis. 2012, 27:215-20. 10.1007/s00384-011-1516-3
5. Acheson AG, Scholefield JH: Management of haemorrhoids. BMJ. 2008, 336:380-5. 10.1136/bmj.39465.674745.80
6. Kaidar-Person O, Person B, Wexner SD: Hemorrhoidal disease: a comprehensive review. J Am Coll Surg. 2007, 204:102-17. 10.1016/j.jamcollsurg.2006.08.022
7. Alonso-Coello P, Zhou Q, Martinez-Zapata MJ, Mills E, Heels-Ansdell D, Johanson JF, Guyatt G: Meta-analysis of flavonoids for the treatment of hemorrhoids. Br J Surg. 2006, 93:909-20. 10.1002/bjs.5578
8. Menyte BB, Gorgul A, Tatlıcıoğlu E, Ayoğlu F, Ünal S: Efficacy of calcium dobesilate in treating acute attacks of hemorrhoidal disease. Dis Colon Rectum. 2001, 44:1489-95. 10.1007/BF02234604
9. Ravindrannath GG, Rahul BG: Prevalence and risk factors of hemorrhoids: a study in a semi-urban centre. Int Surg J. 2018, 5:496-9. 10.18203/2549-2902.isj20180359
10. Ali SA, Shoeb MF: Study of risk factors and clinical features of hemorrhoids. Int Surg J. 2017, 4:1936-9. 10.18203/2349-2902.isj20172051

11. Khan RM, Itrat M, Ansari AH, Zulkiflie M: A study on associated risk factors of haemorrhoids. J Biol Sci Opinion. 2015, 5:36-8. 10.7897/2521-6228.0218

12. Sarabia M, León S, Vivas J, et al.: Calcium dobesilate versus purified flavonoid fraction of diosmin in the treatment of hemorrhoidal crises: a randomized, controlled study with an initial double-blind, double-dummy period. Curr Ther Res. 2001, 62:524-9. 10.1016/S0011-393X(01)80051-5

13. Patel HD, Bhedi AN, Chauhan AP, Joshi RM: Calcium dobesilate in symptomatic treatment of hemorrhoidal disease: an interventional study. Nat J Med Res. 2013, 3:42-4.